Business Wire · VIR · November 8, 2026

Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta

Get the app for more

Explore stock news, insights and company research.